The First Affiliated Hospital of Soochow University: all 258 studies

Page 1 of 3. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.

• BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic LeukemiaRecruitingNCT07854652Phase 1
• Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingNCT07774234Phase 2
• A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNCT07762508Not applicable
• Safety and Feasibility of FMT for Immune Recovery After HSCTNot yet recruitingNCT07755319Phase 1/2
• A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingNCT07709884Phase 4
• CMV-CMI in csCMVi After HSCTRecruitingNCT07688759
• VA Consolidation in Intermediate-Risk AMLRecruitingNCT07672262Phase 2
• Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and PrognosisRecruitingNCT07670130
• Younger vs. Older Donors in Allo-HSCT: TTENot yet recruitingNCT07666568
• Cousin vs. Sibling Donors in Haplo-HSCTNot yet recruitingNCT07662382
• Endofaster Robot for Gastroesophageal Submucosal Tumors: A Randomized Controlled StudyNot yet recruitingNCT07655674Not applicable
• Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple MyelomaRecruitingNCT07652138Phase 1
• Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast CancerRecruitingNCT07647263Phase 2
• Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingNCT07635511Phase 3
• VA Induction and Bridging Transplantation for Hypoplastic/Secondary AMLNot yet recruitingNCT07635485Not applicable
• FMT in Transplant-related Gastrointestinal MucositisEnrolling by invitationNCT07622849
• Romiplostim for Oral TPO-RA Resistant ITPRecruitingNCT07612319Not applicable
• Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell LymphomaNot yet recruitingNCT07609446
• A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07599423Phase 2
• Effect of VR-MBCT in Chronic Nonspecific Low Back PainRecruitingNCT07589790Not applicable
• VABu Conditioning in Elderly AML HSCTRecruitingNCT07583888Phase 2/3
• Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical TrialRecruitingNCT07581756Not applicable
• SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDSNot yet recruitingNCT07575412Phase 2
• A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute LeukemiaNot yet recruitingNCT07573670Phase 2
• Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07564453Phase 2
• SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDSNot yet recruitingNCT07562568Phase 2
• Peripheral Blood KIT-D816V Mutation in Adult Systemic MastocytosisRecruitingNCT07562542
• A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCTRecruitingNCT07559695
• The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single CenterRecruitingNCT07552285
• AI Model for Early Gastric Cancer Diagnosis Using Endoscopic ImagingRecruitingNCT07551466
• U96-CAR-T-Cells For R/R B-ALLNot yet recruitingNCT07511426Phase 1
• A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly PatientsRecruitingNCT07500753Not applicable
• A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic AnemiaRecruitingNCT07499284Not applicable
• Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationRecruitingNCT07499271Phase 2
• Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLNot yet recruitingNCT07486479Phase 3
• MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibRecruitingNCT07463651Phase 3
• Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07454018Phase 2
• Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AMLRecruitingNCT07451912Phase 1/2
• Venetoclax Combined With Azacitidine for Consolidation Therapy in AMLRecruitingNCT07425782Phase 2
• Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AARecruitingNCT07400341Phase 2
• Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT PatientsRecruitingNCT07400328Phase 2
• Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.RecruitingNCT07372365Phase 2
• Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLRecruitingNCT07372352Phase 2
• U69-CART-Cells For R/R T-ALLRecruitingNCT07350863Phase 1
• Clinical Study of 68Ga-labeled Novel Nectin-4 Bicyclic Peptide PET/CT for Imaging of Solid Tumors With High Nectin-4 ExpressionEnrolling by invitationNCT07319130Not applicable
• Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaRecruitingNCT07270835Phase 4
• BY002 IIT Study in R/R Acute LeukemiaRecruitingNCT07270770Phase 1
• Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCLRecruitingNCT07255963Phase 2
• Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune ThrombocytopeniaRecruitingNCT07206823Not applicable
• Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingNCT07159620Phase 2
• Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute LeukemiaRecruitingNCT07101497Phase 2
• Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.RecruitingNCT07074496Early Phase 1
• Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSLRecruitingNCT07074470Not applicable
• Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL PatientsRecruitingNCT07074457Not applicable
• RN1201 Injection in the Treatment of Antibody-Mediated DiseasesRecruitingNCT07072247Phase 1
• Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL PatientsRecruitingNCT07072221Not applicable
• Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCLRecruitingNCT07072208Not applicable
• Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHLRecruitingNCT07059741Not applicable
• A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid LeukemiaRecruitingNCT07028073Phase 1/2
• A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma PatientsNot yet recruitingNCT07018271Not applicable
• A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic DermatitisRecruitingNCT07015762Phase 1
• A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With AsthmaRecruitingNCT07015749Phase 1
• The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsNot yet recruitingNCT07015021Not applicable
• a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid LeukemiaRecruitingNCT07007949Phase 2
• Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingNCT06985485Phase 2
• Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)RecruitingNCT06960369Phase 1
• Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic LymphohistiocytosisNot yet recruitingNCT06951971Phase 2/3
• A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple MyelomaNot yet recruitingNCT06925958Not applicable
• A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AMLRecruitingNCT06879847Not applicable
• Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid LeukemiaNot yet recruitingNCT06841952Not applicable
• Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute LeukemiaRecruitingNCT06816134Phase 2
• Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCTRecruitingNCT06812598Not applicable
• Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With DiarrheaRecruitingNCT06757491Not applicable
• A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaRecruitingNCT06730256Early Phase 1
• The Real-world Study of Rimegepant Treatment in Female Migraine Patients of ChinaNot yet recruitingNCT06728345
• Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaRecruitingNCT06696833Early Phase 1
• The Impact of Local Anesthetic Solution Temperature on Epidural-related Maternal FeverRecruitingNCT06682416Not applicable
• Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) PatientsRecruitingNCT06682156
• Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCLRecruitingNCT06682130Phase 2
• BuCy Vs. TBICy for Allo-HSCT in T-ALL PatientsNot yet recruitingNCT06673459Phase 3
• Dapagliflozin in Allo-HCT for aGVHDRecruitingNCT06626737Phase 2
• Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALLRecruitingNCT06578546Phase 2
• Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT06559644Early Phase 1
• A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic DiseasesRecruitingNCT06548958Not applicable
• Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsEnrolling by invitationNCT06544109Phase 2/3
• Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06532552Phase 2
• Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALLRecruitingNCT06507514Phase 1
• Modified DEP Regimens for the Treatment of Hemophagocytic LymphohistiocytosisNot yet recruitingNCT06504030Phase 4
• A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.RecruitingNCT06497452
• CMOP±R in the Treatment of Untreated Non-Hodgkin's LymphomaRecruitingNCT06486337Phase 2
• Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLEnrolling by invitationNCT06468943Phase 2
• Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
• Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML PatientsRecruitingNCT06394011Phase 2
• Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALLRecruitingNCT06393985Phase 2
• Haplo-cord HCT vs. Haplo-HCT for T-ALL PatientsRecruitingNCT06381817Phase 3
• Effects of an Oral Multi-vitamin Carbohydrate Beverage on Intraoperative Nausea and VomitingNot yet recruitingNCT06333626Not applicable
• VAC Regimen for AML Patients Who Failed to Response to VA RegimenRecruitingNCT06220162Phase 2
• Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCTRecruitingNCT06143501
• TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCTRecruitingNCT06125483Not applicable
• CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).RecruitingNCT06078306Phase 2

← The First Affiliated Hospital of Soochow University overview and focus areas